The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Payers in the private sector have historically tried to get providers to pay the generic price for branded multisource products using maximum allowable cost (MAC) terminology in their contracts as soon as the branded drugs have a generic source. This has caused problems for providers that still have...
Both Barack Obama and John McCain have made negative statements about the pharmaceutical industry. Both also favor drug importation into the U.S. from countries with price controls. The emergence of global wholesalers makes it more likely for an importation law to pass, despite the dangers to supply...
A new OIG report highlights supposed “excess” payments by Medicare’s cost-plus drug reimbursement model, giving us a peek at the time path of generic margins in the Part B program. However, OIG overstates their case by ignoring the powerful incentives for rapid generic substitution that are created...
Representatives Steve Buyer (R-IN), Gene Green (D-TX), Jim Matheson (D-UT), and Mike Rogers (R-MI) co-sponsored H.R. 5839 Safeguarding America’s Pharmaceuticals Act of 2008. H.R. 5839 was going to be incorporated into other related FDA legislation, but intense behind-the scenes lobbying by the pharmacy...
Implementation of California’s e-pedigree law has (probably) been pushed back to 2015. The widespread industry support for the bill makes me believe that the 2015 date might actually stick. The more realistic timeline should encourage pharmaceutical manufacturers to get serious about mass serialization...
Healthways reported lower than expected earnings in its current quarter and analysts are pointing to a tightening in the healthcare markets and the fact that Healthways products are expensive. Does this really make sense?
1) Concerns over the new FDA restrictions on ESA's is being overstated. 2) Amgen will continue to do well in the ESA market place, in spite of these changes. 3) J&J will receive the brunt of these changes, strictly because of their market concentration in the oncology market. 4) ...
The VA has already won many awards for an electronic medical records system, which tax payers have already paid for. Adopting the VA "CPRS" program would save the taxpayers and the private sector hundreds of billions of dollars.
Considering the effects of fosamax and other bisphosphonates on bone remodeling, it is not at all surprising to see problems arising with the long term use of these agents.